OXERVATE

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania, Poland.

Active ingredients

The drug OXERVATE contains one active pharmaceutical ingredient (API):

1	Cenegermin UNII B6E7K36KT8 - CENEGERMIN
	Cenegermin, a recombinant form of human nerve growth factor. Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (i.e. TrkA) and low-affinity (i.e. p75NTR) nerve growth factor receptors. The treatment with cenegermin, administered as eye drops, is intended to allow restoration of corneal integrity.
	Read more about Cenegermin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OXERVATE Eye drops, solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01XA24		S Sensory organs → S01 Ophthalmologicals → S01X Other ophthalmologicals → S01XA Other ophthalmologicals
Discover more medicines within S01XA24

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1749764
FR	Base de données publique des médicaments	60963595
IL	מִשְׂרַד הַבְּרִיאוּת	8523
IT	Agenzia del Farmaco	045383015
LT	Valstybinė vaistų kontrolės tarnyba	1083402
PL	Rejestru Produktów Leczniczych	100392037
US	FDA, National Drug Code	71981-020